Fortis Healthcare Approves Unaudited Standalone & Consolidated Results for Q1 Ended June 30, 2025
The financial results and auditor appointment have a moderate impact on the company's operations and investor sentiment.
The announcement primarily discusses the approval of financial results showing increased revenue and profit compared to the previous year. The appointment of Tax Auditors is also a routine positive corporate governance activity.
* Fortis Healthcare Limited's Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. * M/s. B S R & Co. LLP appointed as the Tax Auditors of the Company for Financial Year 2024-25. * Standalone Revenue from operations is ₹43,303 lacs for the quarter ended June 30, 2025 as compared to ₹33,340 lacs for the quarter ended June 30, 2024. * Net profit for the period from continuing operations is ₹5,188 lacs for the quarter ended June 30, 2025 as compared to ₹2,683 lacs for the quarter ended June 30, 2024. * Earnings per equity share for continuing operations is ₹0.69 * The company acquired 'Fortis' brand and allied trademarks for ₹20,000 lacs.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.